SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
出版年份 2023 全文链接
标题
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-05-12
DOI
10.3389/fimmu.2023.1174138
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SLAMF6/Ly108 promotes the development of hepatocellular carcinoma via facilitating macrophage M2 polarization
- (2022) Qi Meng et al. Oncology Letters
- CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
- (2022) Julie O’Neal et al. LEUKEMIA
- Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives
- (2022) Pooya Farhangnia et al. Expert Review of Clinical Immunology
- Strong prognostic value of SLAMF7 protein expression in patients with lymph node‑positive breast cancer
- (2022) Mourad Assidi Oncology Letters
- Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma
- (2021) Mariko Ishibashi et al. Cancers
- CD84 is a regulator of the immunosuppressive microenvironment in Multiple Myeloma
- (2021) Hadas Lewinsky et al. JCI Insight
- Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
- (2021) Sophia Danhof et al. ANNALS OF HEMATOLOGY
- Identification of a tumor microenvironment-related gene signature to improve the prediction of cervical cancer prognosis
- (2021) Qian Chen et al. Cancer Cell International
- The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5
- (2021) Lihi Radomir et al. Nature Communications
- Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions
- (2021) Emma Hajaj et al. Cancer Immunology Research
- Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases
- (2021) Lin Sun et al. Frontiers in Immunology
- SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity
- (2021) Yevgeniya Gartshteyn et al. Frontiers in Immunology
- Circulating and Tumor-Infiltrating NK Cells From Clear Cell Renal Cell Carcinoma Patients Exhibit a Predominantly Inhibitory Phenotype Characterized by Overexpression of CD85j, CD45, CD48 and PD-1
- (2021) Andrea Ziblat et al. Frontiers in Immunology
- GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma
- (2021) Zhaowei Wang et al. Journal for ImmunoTherapy of Cancer
- Acute myeloid leukemia immune escape by epigenetic CD48 silencing
- (2020) Zhiding Wang et al. CLINICAL SCIENCE
- SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma
- (2020) Mariko Ishibashi et al. MOLECULAR CANCER RESEARCH
- CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
- (2020) Sabarinath V. Radhakrishnan et al. Nature Communications
- SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma
- (2020) Akihiko Sugimoto et al. Scientific Reports
- SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a novel T cell checkpoint
- (2020) Emma Hajaj et al. eLife
- CD244 represents a new therapeutic target in head and neck squamous cell carcinoma
- (2020) Laura Agresta et al. Journal for ImmunoTherapy of Cancer
- In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome
- (2020) Gian Matteo Rigolin et al. BRITISH JOURNAL OF HAEMATOLOGY
- SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes
- (2020) Sabina Sandigursky et al. CLINICAL IMMUNOLOGY
- SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2
- (2020) Lisa von Wenserski et al. LEUKEMIA
- Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7
- (2020) Christina Amatya et al. MOLECULAR THERAPY
- SLAMF1 contributes to cell survival through the AKT signaling pathway in Farage cells
- (2020) Heejei Yoon et al. PLoS One
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
- (2020) Meletios A. Dimopoulos et al. Blood Cancer Journal
- SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment
- (2020) Patrick O’Connell et al. JOURNAL OF IMMUNOLOGY
- AML1-ETO inhibits acute myeloid leukemia immune escape by CD48
- (2020) Zhiding Wang et al. LEUKEMIA & LYMPHOMA
- SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells
- (2020) Dazun Shi et al. Cancer Management and Research
- Human innate lymphoid cell precursors express CD48 that modulates ILC differentiation through 2B4 signaling
- (2020) Dejene M. Tufa et al. Science Immunology
- Sensitivity of chronic lymphocytic leukemia cells to chemotherapeutic drugs ex vivo depends on expression status of cell surface receptors
- (2020) V. Shcherbina et al. Experimental Oncology
- NK cell recognition of hematopoietic cells by SLAM-SAP families
- (2019) Shasha Chen et al. Cellular & Molecular Immunology
- SLAMF6 clustering is required to augment T cell activation
- (2019) Matthew A. Dragovich et al. PLoS One
- SLAMF9 regulates pDC homeostasis and function in health and disease
- (2019) Lital Sever et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Upregulation of SLAMF3 on human T cells is induced by palmitic acid through the STAT5-PI3K/Akt pathway and features the chronic inflammatory profiles of type 2 diabetes
- (2019) Tong Zhou et al. Cell Death & Disease
- SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer
- (2019) Burcu Yigit et al. Cancer Immunology Research
- The Checkpoint Regulator SLAMF3 Preferentially Prevents Expansion of Auto-Reactive B Cells Generated by Graft-vs.-Host Disease
- (2019) Ninghai Wang et al. Frontiers in Immunology
- TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression
- (2019) Chin-Han Huang et al. IMMUNOBIOLOGY
- Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma
- (2019) Tatiana Pazina et al. Cancer Immunology Research
- Bone marrow dendritic cells support the survival of chronic lymphocytic leukemia cells in a CD84 dependent manner
- (2019) Avital F. Barak et al. ONCOGENE
- Signalling lymphocyte activation molecule family member 9 is found on select subsets of antigen‐presenting cells and promotes resistance to Salmonella infection
- (2019) Timothy J. Wilson et al. IMMUNOLOGY
- SLAM family member 8 is involved in oncogenic KIT-mediated signalling in human mastocytosis
- (2018) Akihiko Sugimoto et al. EXPERIMENTAL DERMATOLOGY
- SLAMF1 is required for TLR4-mediated TRAM-TRIF–dependent signaling in human macrophages
- (2018) Maria Yurchenko et al. JOURNAL OF CELL BIOLOGY
- Signaling lymphocytic activation molecules Slam and cancers: friends or foes?
- (2018) Gregory Fouquet et al. Oncotarget
- Signaling Lymphocyte Activation Molecule Family 5 Enhances Autophagy and Fine-Tunes Cytokine Response in Monocyte-Derived Dendritic Cells via Stabilization of Interferon Regulatory Factor 8
- (2018) Zsofia Agod et al. Frontiers in Immunology
- Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma
- (2018) Cun-Yi Zou et al. CNS Neuroscience & Therapeutics
- The novel immunoglobulin super family receptor SLAMF9 identified in TAM of murine and human melanoma influences pro-inflammatory cytokine secretion and migration
- (2018) Claudia Dollt et al. Cell Death & Disease
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- SLAMF1 engagement inhibits T cell-B cell interaction and diminishes IL-6 production and plasmablast differentiation in systemic lupus erythematosus
- (2018) Maria P. Karampetsou et al. Arthritis & Rheumatology
- Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages
- (2018) Xiaokang Zeng et al. Cellular & Molecular Immunology
- SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?
- (2018) Inna Gordiienko et al. CLINICAL IMMUNOLOGY
- CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia
- (2018) Hadas Lewinsky et al. JOURNAL OF CLINICAL INVESTIGATION
- The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment
- (2018) Laura Agresta et al. Frontiers in Immunology
- Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
- (2018) Kerry S. Campbell et al. Frontiers in Immunology
- The interplay of CD150 and CD180 receptor pathways contribute to the pathobiology of chronic lymphocytic leukemia B cells by selective inhibition of Akt and MAPK signaling
- (2017) Inna Gordiienko et al. PLoS One
- Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
- (2017) Michael Peled et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety issues and management of toxicities associated with new treatments for multiple myeloma
- (2017) Annamaria Brioli et al. Expert Review of Hematology
- LMP1+SLAMF1high cells are associated with drug resistance in Epstein-Barr virus-positive Farage cells
- (2017) Heejei Yoon et al. Oncotarget
- Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
- (2017) Sabarinath Venniyil Radhakrishnan et al. OncoImmunology
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma
- (2016) María-Victoria Mateos et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study
- (2016) Jesus Berdeja et al. Clinical Lymphoma Myeloma & Leukemia
- Elotuzumab for the treatment of multiple myeloma
- (2016) Yucai Wang et al. Journal of Hematology & Oncology
- T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
- (2016) Claudia Zelle-Rieser et al. Journal of Hematology & Oncology
- CD84 mediates CLL-microenvironment interactions
- (2016) A Marom et al. ONCOGENE
- Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs
- (2016) Grégory Fouquet et al. Oncotarget
- A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells
- (2016) Burcu Yigit et al. Oncotarget
- SLAMF4 Is a Negative Regulator of Expansion of Cytotoxic Intraepithelial CD8+ T Cells That Maintains Homeostasis in the Small Intestine
- (2015) Michael S. O’Keeffe et al. GASTROENTEROLOGY
- SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response
- (2015) Cinzia Bologna et al. JOURNAL OF CLINICAL INVESTIGATION
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of CD150 in Tumors of the Central Nervous System: Identification of a Novel Isoform
- (2015) Olga Romanets-Korbut et al. PLoS One
- CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
- (2015) Sara Yousef et al. Human Vaccines & Immunotherapeutics
- Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
- (2015) Ninghai Wang et al. Frontiers in Immunology
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study
- (2015) Paul G Richardson et al. Lancet Haematology
- Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
- (2015) Guoxing Wang et al. PLoS One
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization
- (2014) Luis-Alberto Pérez-Quintero et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Engagement of SLAMF2/CD48 Prolongs the Time Frame of Effective T Cell Activation by Supporting Mature Dendritic Cell Survival
- (2014) K. Kis-Toth et al. JOURNAL OF IMMUNOLOGY
- Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells
- (2014) Huaijian Guo et al. MOLECULAR AND CELLULAR BIOLOGY
- Fine Specificity and Molecular Competition in SLAM Family Receptor Signalling
- (2014) Timothy J. Wilson et al. PLoS One
- Phenotypic T Cell Exhaustion in a Murine Model of Bacterial Infection in the Setting of Pre-Existing Malignancy
- (2014) Rohit Mittal et al. PLoS One
- SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors
- (2014) Jaime De Calisto et al. Frontiers in Immunology
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150/signaling lymphocytic activation molecule
- (2013) Satoshi Takeda et al. CANCER SCIENCE
- Measles Virus Entry Through the Signaling Lymphocyte Activation Molecule Governs Efficacy of Mantle Cell Lymphoma Radiovirotherapy
- (2013) Tanner S Miest et al. MOLECULAR THERAPY
- CD84 is a survival receptor for CLL cells
- (2013) I Binsky-Ehrenreich et al. ONCOGENE
- Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression
- (2013) Ingrid Marcq et al. PLoS One
- NK cell cytotoxicity mediated by 2B4 and NTB-A is dependent on SAP acting downstream of receptor phosphorylation
- (2013) Stephan Meinke et al. Frontiers in Immunology
- A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma
- (2012) Jooeun Bae et al. BRITISH JOURNAL OF HAEMATOLOGY
- Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions
- (2012) Yan Wu et al. HEPATOLOGY
- The Adaptor SAP Controls NK Cell Activation by Regulating the Enzymes Vav-1 and SHIP-1 and by Enhancing Conjugates with Target Cells
- (2012) Zhongjun Dong et al. IMMUNITY
- The Receptor Ly108 Functions as a SAP Adaptor-Dependent On-Off Switch for T Cell Help to B Cells and NKT Cell Development
- (2012) Robin Kageyama et al. IMMUNITY
- CD3-T Cell Receptor Co-stimulation through SLAMF3 and SLAMF6 Receptors Enhances RORγt Recruitment to theIL17APromoter in Human T Lymphocytes
- (2012) Madhumouli Chatterjee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
- (2012) Andrzej J. Jakubowiak et al. JOURNAL OF CLINICAL ONCOLOGY
- Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- (2012) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins
- (2012) M Schoenhals et al. LEUKEMIA
- SLAM Family Receptors and SAP Adaptors in Immunity
- (2011) Jennifer L. Cannons et al. Annual Review of Immunology
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- CD48 as a novel molecular target for antibody therapy in multiple myeloma
- (2011) Naoki Hosen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma
- (2011) D. Atanackovic et al. HAEMATOLOGICA
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- Increased Expression of SLAM Receptors SLAMF3 and SLAMF6 in Systemic Lupus Erythematosus T Lymphocytes Promotes Th17 Differentiation
- (2011) M. Chatterjee et al. JOURNAL OF IMMUNOLOGY
- Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice
- (2011) Je-In Youn et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Autophagy in immunity and inflammation
- (2011) Beth Levine et al. NATURE
- Optimal Germinal Center Responses Require a Multistage T Cell:B Cell Adhesion Process Involving Integrins, SLAM-Associated Protein, and CD84
- (2010) Jennifer L. Cannons et al. IMMUNITY
- CD150 regulates JNK1/2 activation in normal and Hodgkin's lymphoma B cells
- (2010) Mariya Y Yurchenko et al. IMMUNOLOGY AND CELL BIOLOGY
- Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry
- (2010) Laia Llinàs et al. IMMUNOLOGY LETTERS
- Homotypic Cell to Cell Cross-talk Among Human Natural Killer Cells Reveals Differential and Overlapping Roles of 2B4 and CD2
- (2010) Eun-Ok Kim et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Germinal Center T Follicular Helper Cell IL-4 Production Is Dependent on Signaling Lymphocytic Activation Molecule Receptor (CD150)
- (2010) I. Yusuf et al. JOURNAL OF IMMUNOLOGY
- SLAM is a microbial sensor that regulates bacterial phagosome functions in macrophages
- (2010) Scott B Berger et al. NATURE IMMUNOLOGY
- SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions
- (2010) Cynthia Detre et al. Seminars in Immunopathology
- SLAM-Family Receptors: Immune Regulators with or without SAP-Family Adaptors
- (2010) A. Veillette Cold Spring Harbor Perspectives in Biology
- 2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells
- (2009) B. Altvater et al. CLINICAL CANCER RESEARCH
- Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
- (2009) F. van Rhee et al. MOLECULAR CANCER THERAPEUTICS
- Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function
- (2009) Mario-Ernesto Cruz-Munoz et al. NATURE IMMUNOLOGY
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells
- (2008) Jordi Sintes et al. EXPERIMENTAL HEMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now